VTRS - Theravance Mylan settle patent litigation over COPD drug Yupelri
2023-10-30 18:50:40 ET
More on Theravance Biopharma, Teva Pharmaceutical, etc.
- Viatris: Get Paid 5%, Before Growth Materializes
- Viatris' Survival Guide: Strategic Divestitures And Margins
- Viatris: Generic Semaglutide Could Become The Poor Man's Option For Weight Loss
- Viatris downgraded at BofA citing business transition
- Alvotech upgraded at Citi citing FDA nod for biosimilars
For further details see:
Theravance, Mylan settle patent litigation over COPD drug Yupelri